stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) Total debt
Penumbra, Inc.'s total debt at the end of fiscal 2025 was $20.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $19.0M. Over the past ten years it has ranged from $20.7M (fiscal 2025) to $27.1M (fiscal 2020) — the current reading is the lowest in ten years. Penumbra, Inc. ranks 77th of 147 Medical Devices companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $20.7M | (4.68%) |
| FY2024 | $21.7M | (8.23%) |
| FY2023 | $23.7M | (4.77%) |
| FY2022 | $24.9M | (6.25%) |
| FY2021 | $26.5M | (2.01%) |
| FY2020 | $27.1M | 1.19% |
| FY2019 | $26.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $19.0M | (3.04%) |
| Jun 2026 | $19.6M | (2.93%) |
| Mar 2026 | $20.2M | (2.38%) |
| Dec 2025 | $20.7M | (2.40%) |
| 27 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $3.2B |
| BRKR Bruker Corporation compare | $1.7B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $1.2B |
| BIO Bio-Rad Laboratories, Inc. compare | $1.2B |
| PODD Insulet Corporation compare | $962.1M |
| GMED Globus Medical, Inc. compare | $443.4M |
| TXG 10x Genomics compare | $98.0M |
| GKOS Glaukos Corporation compare | $66.9M |
| PEN Penumbra, Inc. | $19.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement